QURE
uniQure N.V.
NASDAQ · Healthcare · Biotechnology · NL
$44.50
−0.80%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 18.7M | 16.1M | 27.1M | 15.8M | 106.5M |
| Cost of Revenue | 14.4M | 1.7M | 18.3M | 13.6M | 3.3M |
| Gross Profit | 4.3M | 14.4M | 8.8M | 2.2M | 103.1M |
| Operating Expenses | |||||
| R&D Expense | 131.3M | 140.7M | 143.8M | 214.9M | 197.6M |
| SG&A Expense | 75.5M | 65.3M | 50.7M | 73.1M | 54.7M |
| General & Admin Expense | — | 65.3M | 50.7M | 73.1M | 54.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 756.0K | (3.8M) | (1.4M) | (2.9M) | (6.0M) |
| Total Operating Expenses | 207.6M | 202.2M | 193.1M | 285.1M | 246.3M |
| Cost and Expenses | 222.0M | 203.9M | 211.4M | 298.7M | 249.6M |
| Operating Income (EBIT) | (203.3M) | (187.8M) | (184.3M) | (282.9M) | (143.2M) |
| Non-Operating | |||||
| Interest Income | 19.6M | 17.0M | 21.4M | 19.6M | 609.0K |
| Interest Expense | 59.7M | 62.0M | 63.7M | 41.6M | 11.7M |
| Net Interest Income | (40.1M) | (45.0M) | (42.3M) | (22.0M) | (11.1M) |
| Other Non-Op Income/Expense | (41.8M) | (5.5M) | (52.8M) | (23.7M) | 14.9M |
| Non-Operating Income (excl Interest) | (7.8M) | (56.5M) | (10.9M) | (17.9M) | (26.6M) |
| EBT (Pre-Tax Income) | (245.2M) | (193.3M) | (237.1M) | (306.6M) | (128.3M) |
| Income Tax Expense | 7.0M | 5.6M | 2.4M | 1.9M | (1.5M) |
| Bottom Line | |||||
| Net Income | (252.2M) | (199.0M) | (239.6M) | (308.5M) | (126.8M) |
| Earnings from Cont. Ops | (252.2M) | (199.0M) | (239.6M) | (308.5M) | (126.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (252.2M) | (199.0M) | (239.6M) | (308.5M) | (126.8M) |
| Per Share | |||||
| Basic EPS | ($4.04) | ($3.46) | ($4.92) | ($6.47) | ($2.71) |
| Diluted EPS | ($4.04) | ($3.46) | ($4.92) | ($6.47) | ($2.71) |
| Revenue Per Share | $0.28 | $0.28 | $0.56 | $0.33 | $2.28 |
| Shares | |||||
| Basic Shares Outstanding | 66.2M | 57.5M | 48.6M | 47.7M | 46.7M |
| Diluted Shares Outstanding | 66.2M | 57.5M | 48.6M | 47.7M | 46.7M |
| Profitability Metrics | |||||
| EBITDA | (181.1M) | (116.6M) | (160.7M) | (253.1M) | (108.0M) |
| D&A | 14.5M | 14.8M | 12.6M | 11.9M | 8.5M |
| EBIT | (195.5M) | (131.3M) | (173.4M) | (265.0M) | (116.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026